New treatments for cutaneous human papillomavirus infection

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 3, 2004, Pages 262-264

  Majewski, S ^a   Jablonska, S ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA INTERFERON; CIDOFOVIR; CIMETIDINE; DIPHENCYPRONE; ETRETINATE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PODOPHYLLOTOXIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS VACCINE;

ANGIOGENESIS; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BURNING SENSATION; CELLULAR IMMUNITY; CONDYLOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EDITORIAL; EROSION; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; SKIN CANCER; SKIN INFLAMMATION; SKIN SENSITIZATION; SKIN ULCER; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VERRUCA VULGARIS; WART VIRUS;

CIMETIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERONS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; WARTS;

EID: 2442501667     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00841.x     Document Type: Editorial

References (24)

1. Arany I, Brysk M, Arrastia C et al. Cidofovir regulates expression of various cyclins in human papillomavirus-infected keratinocytes. J Invest Dermatol 1999; 112: 604.
2. Bouwes Bavinck JN, Berkhout RJM. HPV infections and immunosuppression. Clin Dermatol 1997; 15: 427-437.
3. Cirelli R, Tyring SK. Interferons in human papillomavirus infections. Antiviral Res 1994; 24: 191-204.
4. Gross G. Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 1997; 40: 368-377.
5. Stanley MA. Mechanism of action of imiquimod. Papillomaviruses Report 1999; 10: 23-29.
6. Buckley DA, Keane FM, Munn FM et al. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol 1999; 141: 292-296.
7. Rogers CJ, Gibney MD, Siegfried EC et al. Cimetidine therapy for recalcitrant warts in adults: is it any better than placebo? J Am Acad Dermatol 1999; 41: 123-127.
8. Bigby M. Snake oil for the 21st century. Arch Dermatol 1999; 44: 127-129.
9. Majewski S, Szmurlo A, Marczak M et al. Synergistic effect of retinoids and interferon-alpha on tumor-induced angiogenesis: antiangiogenic effect on HPV-harboring tumor cell lines. Int J Cancer 1994; 57: 81-85.
10. Gross G, Rogozinski T, Schofer H et al. Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. Dermatology 1998; 196: 330-334.
11. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21: 1-14.
12. Richwald GA. Imiquimod. Drugs Today 1999; 35: 497-511.
13. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734-739.
14. Suzuki H, Wang B, Amerio P et al. Imiquimod, a novel topical immune response modifier induces migration of Langerhans' cells. J Invest Dermatol 1998; 110: 556-561.
15. Tomai MA, Ahonen CL, Couture AM et al. Effects of the imidazoquinolines, imiquimod and S-28463 on Th1 and Th2 cytokine response in vitro. J Invest Dermatol 1998; 110: 651-655.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
17. Majewski S, Marczak M, Szmurlo A et al. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996; 106: 1114-1118.
18. Beutner KR, Spruance SL, Hougham AJ et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-239.
19. Tyring SK, Arany I, Stanley MA et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178: 551-555.
20. Hengge UR, Esser S, Schultewolter T et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143: 1026-1031.
21. Mackenzie-Wood A, Kossard S, de Launey J et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-470.
22. Beutner KR, Geisse JK, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
23. Goldstein D, Hertzog P, Tomkinson E et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biology response modification. J Infect Dis 1998; 178: 858-861.
24. Spach DH, Colven R. Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. J Am Acad Dermatol 1999; 40: 818-821.